0.68 USD
▲-0.18+9.95%
盘后 0.64 +4.25%
2026-08-03
市值
$28.36M
市盈率
—
EPS
-1.04
股息率
—
52 周区间
0.60 – 2.45
成交量
352.27K
Beta
1.55
目标价
—
52W 低 0.6052W 高 2.45
价格走势
公司简介
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dem...